Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC

March 18, 2019 – The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer (CRC) to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E-mutant metastatic colorectal cancer (CRC), after failure of 1 or 2 lines of therapy for metastatic disease. Array BioPharma Inc, the manufacturer of … (leggi tutto)